Barton Lewis, MD
Psychiatry · Morehead City, NCNPI 1255397618
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,567 of the $115,143 with a category attached, or 86.5%. AbbVie accounts for 78.8% of it on its own, with 16 other manufacturers making up the rest. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $265.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$91K
- Teva Pharmaceuticals USA, Inc.$20K
- Johnson & Johnson$979
- Alkermes, Inc.$828
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$694
- Otsuka America Pharmaceutical, Inc.$566
- plus $2K from 11 others
What the payments were for
- Consulting fees$3300%
- Speaking & faculty fees$99,56786%
- Travel & lodging$7,3196%
- Food & beverage$7,7347%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 168 | $90,731 |
| Teva Pharmaceuticals USA, Inc. | 94 | $19,796 |
| Johnson & Johnson | 42 | $979 |
| Alkermes, Inc. | 23 | $828 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $694 |
| Otsuka America Pharmaceutical, Inc. | 29 | $566 |
| Vanda Pharmaceuticals Inc. | 16 | $374 |
| Neurocrine Biosciences, Inc. | 15 | $309 |
| E.r. Squibb & Sons, L.L.C. | 18 | $288 |
| Axsome Therapeutics, Inc. | 3 | $266 |
| MDD US Operations, LLC | 1 | $118 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $35 |
| Indivior Inc. | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$88,127
- Austedo XR$18,486
- LYBALVI$1,316
- CAPLYTA$467
- Auvelity$243
- SPRAVATO$224
- VIIBRYD$200
- QELBREE$118
- INGREZZA$116
- AUSTEDO$115
- Fanapt$115
- ABILIFY MAINTENA$115
- ABILIFY ASIMTUFII$115
- VIVITROL$100
How this compares
$115,143 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 141 | $173,478 |
| Austedo XrDeutetrabenazine | 14 | $110,695 |
| IngrezzaValbenazine Tosylate | 12 | $108,833 |
| CaplytaLumateperone Tosylate | 44 | $80,193 |
| AustedoDeutetrabenazine | 11 | $62,280 |
| VraylarCariprazine Hcl | 29 | $48,796 |
| PerserisRisperidone | 13 | $41,706 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $22,588 |
| TrintellixVortioxetine Hydrobromide | 14 | $11,455 |
| DayvigoLemborexant | 14 | $5,202 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 48 | $2,297 |
| Asenapine Maleate | 12 | $2,127 |
| Gabapentin | 64 | $1,167 |
| Buspirone Hcl | 100 | $1,162 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $1,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $979 | $173,478141 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $19,796 | $172,97525 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $309 | $108,83312 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $694 | $80,19344 claims |
| AbbVieVraylar | $90,731 | $48,79629 claims |
| Indivior Inc.Perseris | $28 | $41,70613 claims |
| Alkermes, Inc.Lybalvi | $828 | $22,58814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $11,45514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Morehead City
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.